论文部分内容阅读
[目的]探讨在乳腺癌新辅助化疗中bag-1,bcl-2表达变化的意义。[方法]采用免疫组化SABC法观察了66例乳腺癌新辅助化疗前后bag-1和bcl-2的表达。[结果]新辅助化疗前后bag-1表达有16例发生变化,其中13例由阳性变为阴性,3例由阴性变为阳性。新辅助化疗前后bag-1表达差异有统计学意义。新辅助化疗前后bcl-2表达状态有9例发生变化,其中6例由阳性变为阴性,3例由阴性变为阳性,新辅助化疗前后bcl-2表达无明显差异。[结论]新辅助化疗对bcl-2表达状态无显著性影响,而能显著降低bag-1的表达,bag-1在新辅助化疗机制中可能起重要作用。
[Objective] To investigate the significance of the changes of bag-1 and bcl-2 in neoadjuvant chemotherapy of breast cancer. [Method] The expression of bag-1 and bcl-2 in 66 cases of breast cancer before and after neoadjuvant chemotherapy were observed by immunohistochemical SABC method. [Results] There were 16 cases of bag-1 expression before and after neoadjuvant chemotherapy, of which 13 cases changed from positive to negative and 3 cases changed from negative to positive. Neoadjuvant chemotherapy before and after bag-1 expression difference was statistically significant. Neoadjuvant chemotherapy before and after the expression of bcl-2 in 9 cases changed, of which 6 cases from positive to negative, 3 cases from negative to positive, neoadjuvant chemotherapy before and after bcl-2 expression was no significant difference. [Conclusion] Neoadjuvant chemotherapy has no significant effect on the expression of bcl-2, but can significantly reduce the expression of bag-1. Bag-1 may play an important role in neoadjuvant chemotherapy.